Last reviewed · How we verify

LD-Aminopterin oral capsule

Syntrix Biosystems, Inc. · Phase 2 active Small molecule

LD-Aminopterin oral capsule is a Small molecule drug developed by Syntrix Biosystems, Inc.. It is currently in Phase 2 development. Also known as: racemic 4-Aminopteroylglutamic acid, racemic 4-Aminofolic acid.

At a glance

Generic nameLD-Aminopterin oral capsule
Also known asracemic 4-Aminopteroylglutamic acid, racemic 4-Aminofolic acid
SponsorSyntrix Biosystems, Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about LD-Aminopterin oral capsule

What is LD-Aminopterin oral capsule?

LD-Aminopterin oral capsule is a Small molecule drug developed by Syntrix Biosystems, Inc..

Who makes LD-Aminopterin oral capsule?

LD-Aminopterin oral capsule is developed by Syntrix Biosystems, Inc. (see full Syntrix Biosystems, Inc. pipeline at /company/syntrix-biosystems-inc).

Is LD-Aminopterin oral capsule also known as anything else?

LD-Aminopterin oral capsule is also known as racemic 4-Aminopteroylglutamic acid, racemic 4-Aminofolic acid.

What development phase is LD-Aminopterin oral capsule in?

LD-Aminopterin oral capsule is in Phase 2.

Related